Enrolling

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i).

Enter your city or zip code to find the nearest site

See if You May Qualify

Select a location and then answer a few questions or connect with the study site to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 diabetes
What the trial is testing?
retatrutide, semaglutide
Could I receive a Placebo?
No
Enrollment Goal
1250
Trial Dates
Feb 21, 2024 - Mar 2027
How long will I be in the trial?
The study will last about 26 months and may include up to 24 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Be 18 years or older

  • Have a BMI of ≥ 25.0 kg/m^2

  • Have T2D

  • Have high blood sugar as measured by hemoglobin A1C (HbA1c 7% to 10.5%)

Participants Must Not:

  • Have T1D

  • Have had or plan to have a surgical treatment for obesity

  • Have history of an inflamed pancreas (pancreatitis)

  • Have used any weight loss drugs within the last 3 months

  • Have an eGFR <45 mL/min/1.73 m^2 at screening

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources